EC

EcoR1 Capital Portfolio holdings

AUM $2.06B Turnover 46.34%
1-Year Est. Return 215.32%
This Fund
S&P 500
This Quarter Est. Return
+16.1%
1 Year Est. Return
+215.32%
3 Year Est. Return
+310.3%
5 Year Est. Return
+497.45%
10 Year Est. Return
+14,692.23%
AUM
$1.69B
AUM Growth
+$3.31M
Cap. Flow
-$43.7M
Cap. Flow %
-2.58%
Top 10 Hldgs %
77.31%
Holding
52
New
6
Increased
5
Reduced
4
Closed
15
Avg Time Held Equity + Options
2 years
Top 10 Avg Time Held Equity + Options
1.3 years
Top 20 Avg Time Held Equity + Options
1.9 years
Avg Time Held Equity only
2.1 years
Top 10 Avg Time Held Equity only
1.3 years
Top 20 Avg Time Held Equity only
1.9 years

Top Buys

Rank Stock Value
1
ITOS icon
iTeos Therapeutics
ITOS
+$86.1M
2
ZYME icon
Zymeworks
ZYME
+$68M
3
LKFT icon
Lakefront Biotherapeutics American Depositary Shares
LKFT
+$23.6M
4
ALKS icon
Alkermes
ALKS
+$14.9M
5
VRNA
Verona Pharma
VRNA
+$14.8M

Top Sells

Rank Stock Value
1
PRTA icon
Prothena Corp
PRTA
+$143M
2
SRPT icon
Sarepta Therapeutics
SRPT
+$82.5M
3
ORIC icon
Oric Pharmaceuticals
ORIC
+$12.1M
4
BEAM icon
Beam Therapeutics
BEAM
+$10.3M
5
DNA icon
Ginkgo Bioworks
DNA
+$8.34M

Sector Composition

Rank Sector Weight
1 Healthcare 99.74%
2 Miscellaneous 0.26%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow Held Since
ZYME icon
1
Zymeworks
ZYME
$1.78B
$288M 17.06%
22,970,388
+5,710,840
+33% +$68M
2022 Q4
10 quarters
APLS icon
2
DELISTED
Apellis Pharmaceuticals
APLS
$206M 12.19%
11,895,808
– –
2021 Q4
14 quarters
JAZZ icon
3
Jazz Pharmaceuticals
JAZZ
$13.6B
$181M 10.72%
1,706,469
– –
2023 Q2
8 quarters
ANAB icon
4
AnaptysBio
ANAB
$1.4B
$175M 10.36%
7,880,094
– –
2019 Q4
22 quarters
CRNX icon
5
DELISTED
Crinetics Pharmaceuticals
CRNX
$123M 7.3%
4,288,120
– –
2021 Q4
14 quarters
ITOS icon
6
DELISTED
iTeos Therapeutics
ITOS
$107M 6.31%
+10,688,978
New +$86.1M
2025 Q2
0 quarters
CRSP icon
7
CRISPR Therapeutics
CRSP
$4.86B
$67.6M 4%
1,389,276
– –
2024 Q1
5 quarters
QURE icon
8
uniQure
QURE
$1.45B
$55.6M 3.29%
3,988,971
– –
2024 Q4
2 quarters
TNGX icon
9
Tango Therapeutics
TNGX
$3.74B
$54.4M 3.22%
10,630,736
– –
2020 Q3
19 quarters
XNCR icon
10
Xencor
XNCR
$1.74B
$48.3M 2.86%
6,144,767
– –
2018 Q4
26 quarters
IMNM icon
11
Immunome
IMNM
$2.03B
$37.9M 2.25%
4,079,415
– –
2023 Q4
6 quarters
JANX icon
12
Janux Therapeutics
JANX
$1.05B
$34M 2.01%
1,469,818
– –
2024 Q2
4 quarters
LKFT icon
13
Lakefront Biotherapeutics American Depositary Shares
LKFT
$1.93B
$29M 1.72%
1,036,945
+881,939
+569% +$23.6M
2021 Q3
15 quarters
ETON icon
14
Eton Pharmaceutcials
ETON
$1.51B
$28.9M 1.71%
2,030,544
+91,256
+5% +$1.44M
2024 Q3
3 quarters
KURA icon
15
Kura Oncology
KURA
$855M
$24.2M 1.43%
4,200,000
+1,559,702
+59% +$9.56M
2015 Q4
38 quarters
AKRO icon
16
DELISTED
Akero Therapeutics
AKRO
$23.5M 1.39%
440,000
– –
2025 Q1
1 quarter
MDGL icon
17
Madrigal Pharmaceuticals
MDGL
$10.6B
$22.7M 1.34%
75,000
– –
2024 Q1
5 quarters
NGNE icon
18
Neurogene
NGNE
$444M
$19M 1.13%
1,271,342
– –
2023 Q4
6 quarters
VRNA
19
DELISTED
Verona Pharma
VRNA
$18.9M 1.12%
+200,000
New +$14.8M
2025 Q2
0 quarters
TECX icon
20
Tectonic Therapeutic
TECX
$410M
$18.6M 1.1%
935,121
– –
2024 Q2
4 quarters
ORIC icon
21
Oric Pharmaceuticals
ORIC
$1.2B
$16.4M 0.97%
1,618,068
-1,800,000
-53% -$12.1M
2020 Q2
20 quarters
ALKS icon
22
Alkermes
ALKS
$6.56B
$14.3M 0.85%
+500,000
New +$14.9M
2025 Q2
0 quarters
RNAM
23
DELISTED
Avidity Biosciences
RNAM
$14.2M 0.84%
500,000
-57,576
-10% -$1.72M
2024 Q1
5 quarters
MBX icon
24
MBX Biosciences
MBX
$2.35B
$13.1M 0.78%
1,149,794
-109,479
-9% -$1.12M
2024 Q3
3 quarters
VYGR icon
25
Voyager Therapeutics
VYGR
$124M
$12.2M 0.72%
3,917,546
– –
2021 Q3
15 quarters
1
2 3

Similar funds

RHJA
Rice Hall James & Associates San Diego, California $2.05B AUM 43.16% 1-Year Est. Return
ST
Spinnaker Trust Portland, Maine $2.06B AUM 24.94% 1-Year Est. Return
ABTD
Arvest Bank Trust Division Dewey, Oklahoma $2.05B AUM 30.62% 1-Year Est. Return
CFA
Capstone Financial Advisors Downers Grove, Illinois $2.05B AUM 19.29% 1-Year Est. Return
DWT
Dorsey & Whitney Trust Sioux Falls, South Dakota $2.05B AUM 30.99% 1-Year Est. Return
RMC
Ribbit Management Company Palo Alto, California $2.05B AUM 4.29% 1-Year Est. Return
SIC
Sigma Investment Counselors Northville, Michigan $2.05B AUM 18.42% 1-Year Est. Return
FWTB
First Western Trust Bank Denver, Colorado $2.05B AUM 0.32% 1-Year Est. Return

EcoR1 Capital's Q2 2025 Portfolio in Review

As of Q2 2025, EcoR1 Capital held 52 positions worth $1.69B, up 0.2% from $1.69B the previous quarter. Its ten largest holdings account for 77% of the portfolio.

EcoR1 Capital's Q2 2025 filing shows 6 new, 5 increased, 4 reduced and 15 closed positions. Its largest new stake was iTeos Therapeutics: 10,688,978 shares worth $107M. The largest sale was Prothena Corp, an estimated $143M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 100% a quarter earlier, followed by Miscellaneous.

  • EcoR1 Capital's largest Q2 2025 buy was iTeos Therapeutics: 10,688,978 shares worth $107M.
  • EcoR1 Capital added most to Zymeworks in Q2 2025, an estimated $68M increase.
  • EcoR1 Capital's biggest Q2 2025 reduction was Oric Pharmaceuticals, cutting an estimated $12.1M.
  • EcoR1 Capital fully exited Prothena Corp in Q2 2025, selling an estimated $143M.
  • EcoR1 Capital's ten largest holdings make up 77% of its $1.69B portfolio in Q2 2025.
  • EcoR1 Capital opened 6 new positions and closed 15 in Q2 2025.
  • EcoR1 Capital's portfolio value rose 0.2% quarter-over-quarter to $1.69B.

Based on EcoR1 Capital's 13F filing for Q2 2025, filed 14 Aug 2025.